Litigation Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Docket		Date Filed	2017-08-16
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,791,270; 9,144,568; 9,265,831; 9,572,797; 9,572,887; 9,597,399
Link to Docket	External link to docket

Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-04-27	394	Opinion	infringement of U.S. Patent Nos. 9,265,831 (the #831 patent), 9,572,797 (the #797 patent), 9,144,568 (the #568 …#568 patent) and 9,597,399 (the #399 patent) by all defendants and infringement of U.S. Patent No. 9,572,887…asserted patents: claims 2, 3, and 5 of the #831 patent; and claims 9 and 11 of the #797 patent. Plaintiffs…asserted patents: claims 11, 18, and 22 of the #568 patent and claim 15 of the #399 patent (by all Defendants…claim 13 of the #399 patent (by Apotex only); and claim 13 of the #887 patent (by Slayback only).	External link to document
2020-07-06	406	Order - -Memorandum and Order	all the patents that were asserted in the case by Plaintiffs except for U.S. Patent No. 8,791,270. The …respectively, with the exception of U.S. Patent No. 8,791,270, which has been resolved by the granting… 8,791,270, which has been resolved by the granting of a consent judgment." D.I. 319 ,r 4. …of the patent that has been asserted by Slayback in this case, with the exception of U.S. Patent No. 8,791,270…either infringe the asserted patents or don't infringe the asserted patents. I note in this regard that	External link to document